Background
Semaglutide is a GLP-1 receptor agonist approved by the FDA under the brand names Ozempic and Wegovy (injections) and Rybelsus and the Wegovy pill (tablets). Compounded semaglutide uses the same molecule but is prepared by a compounding pharmacy. It is most often a weekly injection supplied in vials, and some pharmacies prepare other forms.
Shortage history
Semaglutide injection products were added to the FDA drug shortage list in 2022, as demand grew. While a drug is in shortage, federal law lets compounders make copies of it, and many online weight-loss programs began offering compounded semaglutide in that period.
On February 21, 2025, the FDA determined that the semaglutide shortage was resolved. It gave 503A pharmacies until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop shortage-based compounding. A court denied a request to block the decision on April 24, 2025. See GLP-1 drug shortage.
Availability after the shortage
After the shortage ended, compounded semaglutide remains available through 503A pharmacies when a prescriber orders a version for an individual patient. Under the essentially-copy rule, a 503A pharmacy may not regularly make a product that matches the approved drug. Common differences include a strength not sold by the manufacturer or an added ingredient. The FDA used semaglutide with vitamin B12 as an example in its April 1, 2026 update.
Ingredients and salt forms
The approved semaglutide products contain the base form of semaglutide. The FDA has said that salt forms, such as semaglutide sodium and semaglutide acetate, are different active ingredients and should not be used to compound semaglutide. Pharmacies that compound semaglutide under section 503A must use an ingredient that meets federal standards, such as a component of an approved drug.
Comparison with brand-name semaglutide
Brand-name semaglutide comes in pens or tablets with an FDA-approved label. Compounded semaglutide is not FDA-approved, is labeled by the pharmacy and is made for one patient. Online programs that offer either option are compared on the compounded semaglutide page.
Timeline
- 2022Semaglutide injection added to the FDA drug shortage list.
- February 21, 2025FDA declares the semaglutide shortage resolved.
- April 22, 2025End of 503A shortage-based compounding.
- May 22, 2025End of 503B shortage-based compounding.
Compare compounded semaglutide programs
See also
References
- FDA: Resolution of shortages of semaglutide injection products (February 21, 2025). fda.gov
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026). fda.gov
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss. fda.gov
- FDA: Human drug compounding laws. fda.gov
Last updated . Category: Pharmacy & compounding. Browse all 38 WikiTelehealth entries.